Monitoring antiplatet therapy: What is the best method?

Clinical Pharmacokinetics

Volumn 39, Issue 6, 2000, Pages 445-458

  Mukherjee, D ^a   Moliterno, D J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PYRIDINE DERIVATIVE; TICLOPIDINE; TIROFIBAN; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR;

ANTICOAGULANT THERAPY; BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG CLEARANCE; DRUG RECEPTOR BINDING; FUNCTION TEST; HUMAN; META ANALYSIS; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE RELEASE REACTION; BLOOD CLOTTING PARAMETERS; DRUG ANTAGONISM; DRUG EFFECT;

HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 0034351986     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200039060-00005     Document Type: Review

References (44)

1. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy
2. An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia
3. Platelet GPIIb-IIIa blockers
4. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
5. Clinical trials of IIb/IIIa receptor blockers in patients undergoing angioplasty
6. Coronary intervention and glycoprotein IIb/IIIa integrin blockade
7. Glycoprotein IIb/IIIa receptor antagonists in non-ST elevation acute coronary syndromes and percutaneous revascularisation: A review of trial reports
8. Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology
9. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
10. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group: Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication
11. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators: Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
12. Bleeding complications with platelet glycoprotein IIb/IIIa receptor antagonists
13. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention IMPACT-II: Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II
14. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina: Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators
15. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: Bleeding, reversal, thrombocytopenia, and retreatment
16. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty
17. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina: European Cooperative Study Group
18. Flow cytometric observations on the in vivo use of Fab fragments of a chimaeric monoclonal antibody to platelet glycoprotein IIb-IIIa
19. Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases
20. Platelet GPIIb/IIIa antagonists: The first anti-integrin receptor therapeutics
21. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time
22. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa
23. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents
24. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention
25. Applications of anti-platelet monitoring in catheterization laboratory
26. Substituting isoserine for serine in the thrombin receptor activation peptide SFLLRN confers resistance to aminopeptidase M-induced cleavage and inactivation
27. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors
28. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: The Canadian Lamifiban Study
29. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention
30. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention
31. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men
32. A prospective multicenter study to determine the optimal level of platelet inhibition with GP IIb/IIIa inhibitors in patients undergoing coronary intervention: The GOLD study
33. 2+ on GP IIb-IIIa interactions with integrilin: Enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate
34. PFA-100 system: A new method for assessment of platelet dysfunction
35. Rapid assessment of GPIIb/IIIa blockade: An evaluation of PFA-100 as a point-of-care technology during percutaneous coronary interventions (PCI) - Checkpoint study
36. Assessment of platelet function assays
37. Thrombelastography
38. Monitoring platelet glycoprotein IIb/IIIa-fibrin interaction with tissue factor-activated thromboelastography
39. A modified thromboelastographic method for monitoring c7E3 Fab in heparinized patients
40. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antatgonists on platelet mediated clot strength induced by tissue factor with use of thromboelastography: Diffrentiation among glycoprotein IIb/IIIa antagonists
41. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade
42. Rapid platelet-function assay: An automated and quantitative cartridge-based method
43. The Accumetrics rapid platelet function analyzer (RPFA) to monitor platelet aggregation during oral administration of a GPIIb/IIIa antagonist
44. Assessing the optimal level of platelet inhibition with GPIIb/IIIa inhibitors in patients undergoing coronary intervention: Rationale and design of the GOLD study